VANCOUVER, BC and UTTENWEILER, GERMANY/ACCESSWIRE/June 27, 2022/X Phyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPyto” or the “Company”) is pleased to congratulate Professor Raimar Loebenberg as the 2022 recipient of the CSPS Award for Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta (“UoA”), founder and director of the Drug Development and Innovation Center (DDIC), UoA, and is a director and founder of XPyto since 2018.
The CSPS Leadership Award in Canadian Pharmaceutical Sciences is given to an individual who has demonstrated leadership in advancing the cause of pharmaceutical research and development in Canada. Teacher. Dr. Loebenberg earned a Bachelor of Science in Pharmacy from Johannes Gutenberg University, Mainz, Germany and a Doctor of Pharmacy from Johann Wolfgang Goethe University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Center for Drug Development and Innovation in the Faculty of Pharmacy and Pharmaceutical Sciences. Professor Dr. Loebenberg’s research interests are in biopharmaceuticals to predict oral performance of drugs and plants and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis and leishmanase. He is a co-founder of RS Therapeutics Inc., a foam-based topical drug delivery company.
Recent notable positions of Prof. Dr. Loebenberg include: President of the Canadian Society for Pharmaceutical Sciences from 2014 to 2015; vice-chairman of the United States Pharmacopeia Dietary Supplement Expert Committee from 2016 to 2017; current member of the United States Pharmacopeia Expert Committee on Dietary Supplements; current Vice-Chair of the Traditional Chinese Medicine in Pharmacy Specialty Committee of the World Chinese Medicine Science Foundation; and a current member of Health Canada’s Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.
XPyto is proud to have Professor Dr. Loebenberg on its Board of Directors and to lead its psychedelic medicine program with a multi-pronged approach including GMP drug synthesis, proprietary drug delivery systems, new psychedelic analogue engineering and clinical validation.
About XPyto Therapeutics Corp.
XPyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostics and new investment opportunities in active pharmaceutical ingredients, including: precision transdermal and oral soluble drug formulations; rapid and inexpensive diagnostic tests for infectious diseases and oral health; and the manufacture, standardization and evaluation of psychedelic compounds for the treatment of neurological disorders. The Company has research and development activities in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
X Phyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Email: [email protected]
Telephone: +1 780-818-6422
This press release contains statements that contain forward-looking information within the meaning of applicable Canadian securities laws (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the company’s purpose to build a successful diagnostics, drug distribution and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results differ materially from those projected in the forward-looking statements, including: that the Company may not be successful in developing a commercial product; that selling products may not be a viable business; that the Company may not be able to expand its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources and/or inability to access sufficient capital on favorable terms; currency risks; competition; international risks; and other risks beyond the Company’s control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law. expressly requires. Neither the CSE nor its Market Regulator (as that term is defined in the CSE policies) accepts responsibility for the adequacy or accuracy of this press release.
THE SOURCE: X Phyto Therapeutics Corp.
See the source version on accesswire.com: